PetDx is a molecular diagnostics company based in La Jolla, California, that aims to detect and treat cancer in pets using liquid biopsy. The company’s cutting-edge technology, OncoK9, provides a first-in-class multi-cancer early detection (MCED) test that empowers veterinarians to provide superior care to canine patients. With a simple blood draw, OncoK9 can detect cancer in dogs, revolutionizing the way pet health is diagnosed and treated.
Introducing PetDx
PetDx is a company dedicated to unleashing the power of genomics to improve pet health. The company’s mission is to make early cancer detection a reality for pets, saving lives and improving the quality of life for furry friends and their owners. PetDx’s innovative technology, OncoK9, is the first liquid biopsy test for pets that enables veterinarians to detect cancer using a simple blood draw.
The Need for Early Cancer Detection in Pets
Cancer is one of the leading causes of death in pets, and early detection is crucial for successful treatment. Unfortunately, traditional methods of cancer detection in pets, such as tissue biopsies and imaging tests, are invasive, time-consuming, and expensive. Moreover, these tests often require anesthesia, which poses risks to pets, especially older ones.
OncoK9: The Liquid Biopsy Test for Pets
OncoK9 is a revolutionary liquid biopsy test for pets that uses next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms to detect cancer in dogs. The test analyzes the circulating tumor DNA (ctDNA) in a dog’s blood, allowing veterinarians to detect cancer early, before symptoms appear.
OncoK9 is a non-invasive, painless, and affordable test that can be performed during a routine visit to the veterinarian. It can detect multiple types of cancer, including lymphoma, osteosarcoma, hemangiosarcoma, and mammary cancer, among others. With OncoK9, veterinarians can diagnose cancer early, monitor its progression, and determine the best course of treatment for their patients.
PetDx’s Impact on Pet Health
PetDx’s innovative technology is changing the way pet health is diagnosed and treated. By providing a non-invasive and affordable liquid biopsy test for pets, PetDx is making early cancer detection a reality for pets, improving their quality of life, and prolonging their lives. With OncoK9, pet owners can have peace of mind knowing that their furry friends are receiving the best possible care.
Conclusion
PetDx is a company dedicated to improving pet health through genomics. Its flagship product, OncoK9, is a liquid biopsy test that enables veterinarians to detect cancer in dogs with a simple blood draw. With OncoK9, PetDx is revolutionizing pet health by providing a non-invasive, painless, and affordable test that can detect multiple types of cancer. PetDx’s technology is changing the way pet health is diagnosed and treated, making early cancer detection a reality for pets, and improving their quality of life.
Website: https://petdx.com
Twitter: https://twitter.com/PetDxInc/
Facebook: https://www.facebook.com/PetDxInc
LinkedIn: https://www.linkedin.com/company/petdx
